Fig. 2From: ANCA positive crescentic glomerulonephritis outcome in a Central East European cohort: a retrospective studyAdjusted cumulative kidney survival according to the response to induction therapy (left) and to the need of dialysis at presentation (right). Legend: The median ESRD-free survival time was longer in responders to induction therapy [4.5 (4.1–4.9) vs. 1.0 (0.3–1.6) years; p < 0.0001] and in those who did not need dialysis at presentation [4.1 (3.6–4.7) vs. 0.9 (0.3–1.6) years; p < 0.0001]. ESRD End stage renal diseaseBack to article page